← All trials
NCT00134719
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2005
- Primary completion
- Jul 1, 2007
- Completion date
- Jul 1, 2007
- First posted
- —
- Last posted
- —
- Enrollment
- 1104
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- GlaxoSmithKlineLead sponsor
- GlaxoSmithKlineStudy director
Drugs studied
- haemophilus influenzae type b-neisseria meningitidis serogroups c and y-tetanus-toxoid conjugate vaccine
- pneumococcal 13-valent conjugate vaccine
- pneumococcal 13-valent conjugate vaccine
- glyco-conjugate neisseria meningitidis serogroup c vaccine
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
- live attenuated varicella vaccine
- live attenuated varicella vaccine
- measles, mumps, and rubella vaccine
- measles, mumps, and rubella vaccine
- haemophilus influenzae type b conjugate vaccine
- HibMenCY
- HibMenCY
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.